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Abstract
Background: Hormone replacement therapy use (HRT) is associated with increased breast cancer risk. Our
primary objective was to explore hormone levels in plasma according to HRT use, body mass index (BMI) and
menopausal status. A secondary objective was to validate self-reported questionnaire information on
menstruation and HRT use in the Norwegian Women and Cancer postgenome cohort (NOWAC).
Methods: We conducted a cross-sectional study of sex hormone levels among 445 women aged 48–62 who
answered an eight-page questionnaire in 2004 and agreed to donate a blood sample. The samples were drawn at
the women's local general physician's offices in the spring of 2005 and sent by mail to NOWAC, Tromsø, together
with a two-page questionnaire. Plasma levels of sex hormones and Sex Hormone Binding Globulin (SHBG) were
measured by immunometry. 20 samples were excluded, leaving 425 hormone measurements.
Results: 20% of postmenopausal women were HRT users. The plasma levels of estradiol (E2) increased with an
increased E2 dose, and use of systemic E2-containing HRT suppressed the level of Follicle Stimulating Hormone
(FSH). SHBG levels increased mainly among users of oral E2 preparations. Vaginal E2 application did not influence
hormone levels. There was no difference in BMI between HRT users and non-users. Increased BMI was associated
with increased E2 and decreased FSH and SHBG levels among non-users. Menopausal status defined by the two-
page questionnaire showed 92% sensitivity (95% CI 89–96%) and 73% specificity (95% CI 64–82%), while the eight-
page questionnaire showed 88% sensitivity (95% CI 84–92%) and 87% specificity (95% CI 80–94%). Current HRT
use showed 100% specificity and 88% of the HRT-users had plasma E2 levels above the 95% CI of non-users.
Conclusion: Users of systemic E2-containing HRT preparations have plasma E2 and FSH levels comparable to
premenopausal women. BMI has an influence on hormone levels among non-users. NOWAC questionnaires
provide valid information on current HRT use and menopausal status among Norwegian women who are
between 48 and 62 years old.
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Background
Plasma concentrations of steroid hormones influence the
risk of breast cancer among both premenopausal and
postmenopausal women, and estrogen is regarded as a
carcinogen in cancer development [1,2]. Several epidemi-
ological studies have examined female sex hormone lev-
els, but hormone replacement therapy (HRT) users were
either excluded [3-7] or they were not classified according
to the type of HRT used [8,9]. One exception is a prospec-
tive case-control study nested within the Nurses' Health
Study (NHS) [10]. However, it is uncertain whether
results from the USA can be generalized to the Norwegian
female population, due to different types of HRT prepara-
tion dominating the two markets, i.e. conjugated equine
estrogens in the USA and micronized 17-β-estradiol or
estradiol valerate in Norway. Several clinical studies have
examined the relationship between HRT use and hor-
mone levels, although in relatively small and highly
selected populations [11,12]. Elevated estrogen levels may
also be a result of high body mass index (BMI), through
the conversion of androstenedione to estrone in adipose
tissue [6,13].
The Norwegian Women and Cancer study (NOWAC) is a
population-based, nation-wide cohort study which pro-
spectively measures risk factors and biomarkers by means
of repeat questionnaires and blood sample collection. The
study has previously shown [14] that current use of HRT
is associated with increased breast cancer risk, in agree-
ment with similar observational studies like the Million
Women Study (MWS)[15] and the European Prospective
Investigation into Cancer and Nutrition (EPIC) [16]. It
should be noted that breast cancer risk may differ accord-
ing to differing HRT regimens [17], and that self-reported
use of HRT and menstruation status among NOWAC par-
ticipants has not been validated and described through
hormone levels in plasma. The quality of results from
research into questionnaire information depends heavily
on the questions asked, and validation of the variables
used is essential in this respect [18]. A cross-sectional
descriptive study of hormone levels is also important, to
avoid misclassification of subjects in a subsequent gene
expression analysis of the same material.
In this study, we explore hormone levels in plasma
according to HRT use, BMI and menopausal status. We
further use plasma hormone levels to investigate the
validity of self-reported information on menstruation,
current HRT use and different HRT regimens in the
NOWAC postgenome cohort.
Methods
Study population
The Norwegian Women and Cancer Study (NOWAC) is a
cohort study based on questionnaires mailed to women
who are 30–70 years old [19]. Participants are randomly
drawn from the Central Population Register. From 1991
up until June 2007, 171 977 women had been enrolled in
NOWAC, of whom 167 058 are still participating. Ques-
tionnaire information on diet, lifestyle and the use of
medication is available, with 1–2 repeat measurements at
4–6 year intervals. The NOWAC postgenome cohort con-
sists of 49 233 participants born between 1943 and 1957,
who contributed a blood sample between 2003 and 2006.
Written informed consent is obtained from each partici-
pant and the collection and storing of questionnaire infor-
mation and blood samples is approved by The Regional
Committee for Medical Research Ethics and the Norwe-
gian Data Inspectorate. Statistics Norway obtains updated
information on deaths and migration and performs the
sampling of women, thereby providing a complete fol-
low-up of participants.
The present study is a cross-sectional analysis within the
NOWAC postgenome cohort (Figure 1). Of the 20 391
women who answered an eight-page questionnaire in the
autumn of 2004 (response rate 81%), 17 932 agreed to
donate a blood sample. Women, randomly drawn in
groups of 500, were mailed a blood collection kit and an
accompanying two-page questionnaire in April 2005.
One reminder was mailed after three weeks to non-
responders. The overall response rate was 74%. The two-
page questionnaire included questions regarding meno-
pausal status, smoking, weight, height, use of HRT, oral
contraceptives or other medication, omega-3 intake,
intake of soy or other dietary supplements, and details
concerning blood specimen collection (date, hour, pos-
ture). Our present study included 445 responders from
one group of 500 women (89%); 3.2% declined to partic-
ipate, 0.8% had died or migrated and 7.0% did not
respond. Six samples were excluded due to incompletely
Flow chart of the study population Figure 1
Flow chart of the study population.
20 391 of 25 179 answered an 8-page questionnaire autumn 
2004 (81 %)
17 932 of 20 391 agreed to donate a blood sample (88 %)
Blood collection kit distributed to the participants, 
randomly drawn in groups of 500
425 blood samples 
included in analyses
20 samples excluded
(Incompletely filled
sample tube, lack of
information etc.)
One randomly chosen group: 
445 women (89%) contributed a 
blood sample, April 2005
Total study population 171 977 by June 2007
Study population
Women 48-62 years old in 2005BMC Women's Health 2008, 8:1 http://www.biomedcentral.com/1472-6874/8/1
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filled blood collection tubes. Additionally, 14 women
were excluded due to a lack of information concerning
menopausal status, use of HRT or type of HRT used. This
left plasma sample measurements for 425 women.
Collection and processing of blood samples
The blood samples were drawn at the women's local gen-
eral physician's offices, using the blood collection kit. For
collection of plasma and buffy coat we used a Vacuette®
Coagulation Tube (Greiner Bio-One GmbH, Kremsmüns-
ter, Austria) containing citrate buffer 0.109 mol/L (3.2%);
1 part citrate to 9 parts blood. For collection of RNA we
used a PAXgene™ Blood RNA tube (PreAnalytiX GmbH,
Hombrechticon, Switzerland), which is a BD Vacutainer™
containing a proprietary reagent that immediately stabi-
lizes intracellular RNA. The samples were mailed over-
night to the Institute of Community Medicine at the
University of Tromsø, Norway. The women were
requested not to have their blood samples drawn on
Thursdays and Fridays, in order to avoid a weekend mail
delay. The blood samples were generally received by the
NOWAC biobank staff within 1–2 days (92%). Upon
arrival, the Vacuette® Coagulation Tubes were centrifuged
at 3000 rpm for 15 minutes. Plasma (2 × 1.8 mL) and
buffy coat (1.0 mL) were frozen at -20°C and subse-
quently transferred to -70°C within one week. PAXgene™
Blood RNA tubes were frozen directly at -20°C and trans-
ferred to -70°C without pre-processing. The results of
gene expression analyses will be published at a later stage.
Laboratory analysis
All the hormone analyses were performed at the Depart-
ment of Medical Biochemistry, University Hospital of
North Norway, Tromsø, Norway. Plasma levels of estra-
diol (E2), progesterone (P4) and Follicle Stimulating Hor-
mone (FSH) were measured by immunometry, using an
electrochemiluminescence immunoassay (ECLIA) on
Modular Analytics E170 (Roche Diagnostics GmbH, Man-
nheim, Germany). Plasma levels of Sex Hormone Binding
Globulin (SHBG) were measured by chemiluminescent
immunometric assay (CLIA) on Immulite® 2000 (Diag-
nostic Products Corporation, Los Angeles, CA, USA). The
respective detection limits and analytic coefficients of var-
iation (CV) were 0.018 nmol/L and 5.2% for E2; 0.100 IU/
L and 2.3% for FSH; 0.095 nmol/L and 6.9% for P4; and
0.02 nmol/L and 5.0% for SHBG. For the sake of conven-
ience, SHBG will be referred to as a hormone throughout
this paper. According to the laboratory, the postmenopau-
sal reference values for FSH and E2 were FSH > 26 IU/L
and E2 < 0.20 nmol/L. Three measurements of P4 were
below the detection limit and values were defined as half
of the detection limit (0.048 nmol/l). Two measurements
of SHBG were above the calibration range, and values
were defined as the upper limit of the range (180 nmol/L).
The analysis of Modular Analytics E170 of SHBG is not
validated for citrate plasma by the manufacturer. The
Department of Medical Biochemistry performed a small
verification analysis, using serum and citrate plasma from
21 healthy volunteers (data not published). The results
indicated a good correlation between measurements in
serum and citrate plasma for all hormones measured
(0.9899 ≤ r2 ≤ 0.9997).
Statistical methods
We used SPSS® 14.0 for Windows for the statistical analy-
ses. Geometric mean plasma levels across different catego-
ries of HRT use or BMI were compared using univariate
analysis of covariance (ANCOVA) through the general lin-
ear model approach. Additionally, we used multiple lin-
ear regression to test the association between BMI
(continuous variable) and hormone levels. Covariates
tested for potential confounding: age, alcohol consump-
tion (units per week), parity and BMI (ANCOVA across
HRT categories). In the analysis of the association
between BMI and hormone level among HRT users, we
also included HRT category as a potential confounder.
With the exception of age, only covariates that contrib-
uted significantly to the model were included in the final
analysis. Time since menopause was excluded as a covari-
ate, due to 25% missing values among postmenopausal
women. Sidak corrected post hoc comparisons were used
to determine which group means differed. Levene's
homogeneity-of-variance test was used to check the equal-
ity of group variances. The association between natural
log-transformed hormone levels and time since meno-
pause were tested by partial correlation, controlling for
BMI. Difference in hormone levels according to time since
last HRT dose (0 or 1 day) or fasting (≥10 hours since last
meal [10]), and difference in SHBG level between the use
of oral and other HRT regimens were analysed with Stu-
dent's t-test for independent samples. We used the McNe-
mar's test for correlated proportions to check for
differences in sensitivity and specificity between the two
questionnaires [20]. All p-values are two-tailed and the
level of statistical significance is 5%.
BMI was categorized as underweight (<18.5 kg/m2), over-
weight (≥25.0 kg/m2) and obesity (≥30.0 kg/m2) [21]. The
two lowest categories (underweight and normal weight,
<25.0 kg/m2) were merged, due to there being few under-
weight women.
Menopausal status at blood draw was determined for each
woman, based on her answers in the two-page question-
naire as to whether she still had regular menstrual periods,
whether the periods were irregular or whether they had
stopped. Women were classified as postmenopausal if
their periods had stopped and premenopausal if their
periods were regular. Women with irregular menses wereBMC Women's Health 2008, 8:1 http://www.biomedcentral.com/1472-6874/8/1
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classified as postmenopausal if they were 53 years or
older. This cut-off point was used in a previous NOWAC
report [14], based on the definition used in the MWS [15].
The eight-page questionnaire additionally included ques-
tions regarding the reason why periods had stopped (nat-
ural stop, bilateral oophorectomy, hysterectomy or other
reasons) and the age when periods had stopped. When
classifying according to plasma levels, we used the post-
menopausal reference values, both FSH > 26 IU/L and E2
< 0.20 nmol/L, as cut-off. Women with either high FSH or
low E2 levels were not classified as postmenopausal. The
menopausal classification used as a basis for the between
group analyses is a combination of these classification
procedures. We used the plasma level classification as the
gold standard to validate self-reported menopausal status
defined by each questionnaire.
HRT use was categorized according to E2 content: no HRT,
HRT without E2  (i.e. estriol, tibolone and other pro-
gestogens), E2 for vaginal application, E2 patches (all dos-
ages), oral 1 mg E2  (continuous and sequential
preparations), and oral 2 mg E2 (continuous, but also
sequential preparations with 1 mg E2 in 6 out of 28 tab-
lets).
To assess the validity of HRT use, we compared plasma E2
levels among HRT users with the 95% CI for plasma E2
levels among postmenopausal non-users, and we exam-
ined to what extent plasma E2 levels among non-users
exceeded 0.20 nmol/L.
Results
Table 1 shows an overview of population characteristics.
Based on self-reported age when their periods stopped,
90% of postmenopausal women experiencing natural
menopause were postmenopausal by the age of 53. Figure
2 shows the combined classification of menopausal sta-
tus.
Hormone levels according to HRT use among 
postmenopausal women
Of 331 postmenopausal women, 66 were current HRT
users. Among oral preparations, 84% were combinations
of E2 and norethisterone actetate (NETA), while 16% were
E2-only preparations. Most patches were E2-only prepara-
tions, except one woman using a transdermal combina-
tion of E2 and NETA. Three of the 66 users showed signs
of non-compliance, based on their reported date of last
HRT dose. Six women did not report the date.
Table 2 shows the distribution of women and geometric
mean plasma levels of hormones for each HRT user cate-
gory. The plasma levels of E2 increased with increasing E2
dose (Table 2, Figure 3). Moreover, use of systemically-
administered HRT (patches and tablets) containing E2
suppressed the level of FSH (Table 2, Figure 3). There were
statistically significant differences in P4 and SHBG levels
across categories of HRT use (Table 2), although not in a
dose-dependent manner in the case of P4. The assumption
of homogeneity of variance was violated in the analysis of
E2 and FSH (Levene's test p < 0.01). The ratio between
highest and lowest variance was 7.6 for E2 and 8.7 for
FSH.
The post hoc comparisons showed that there was no dif-
ference in plasma E2 level between vaginal E2 application
and no E2 use (i.e. no HRT use and HRT without E2). The
main difference was between no/vaginal E2 use and sys-
temically administered HRT (p ≤ 0.01). The same ten-
dency was seen for FSH levels, although not as conclusive
as for E2 levels. The post hoc comparison did not reveal
any systematic pattern of differences for P4 and SHBG lev-
els across HRT categories. There was, however, a statisti-
cally significant difference (p = 0.02) in SHBG level
between use of oral HRT (54.5 nmol/L, 95% CI:
45.8–64.9) and the other HRT users (39.8 nmol/L, 95%
CI: 32.6–48.6). There was a borderline significant differ-
ence in E2 level (p = 0.05) between those who had taken
their last tablet on the day of blood sampling (n = 17) and
those who had taken their last tablet the day before (n =
11).
BMI and hormone levels
There was no significant difference in BMI between pre-
menopausal and postmenopausal women (Table 1).
Among postmenopausal women there was no significant
difference in BMI between HRT users (25.1 kg/m2, 95%
CI: 24.0–26.2) and non-users (25.7 kg/m2, 95% CI:
25.2–26.2) (p = 0.30).
Table 1: Characteristics of the study population
Postmenopausal* Pre/perimenopausal* Total
N Mean 95% CI N Mean 95% CI N Mean 95% CI
Age (years) 331 55.8 (55.4–56.2) 94 50.1 (49.6–50.5) 425 54.5 (54.1–54.9)
Years since menopause 247 8.1 (7.4–8.2) - - - - - -
BMI (kg/m2) 331 25.6 (25.1–26.0) 93 25.2 (24.2–26.1) 424 25.5 (25.1–25.9)
* Defined by the combined classification based on both questionnaires and hormone levels (Fig. 2 level c)BMC Women's Health 2008, 8:1 http://www.biomedcentral.com/1472-6874/8/1
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Among non-users, there was a significant difference in
FSH and SHBG levels across the three categories of BMI,
but not in E2 or P4 levels (Table 3). The regression coeffi-
cients (β) showed that one unit increase in BMI was signif-
icantly associated with a -3.5% decreased FSH level (95%
CI: -4.5% – -2.4%), a -5.4% decreased SHBG level (95%
CI: -6.6% – -4.3%), and a 1.6% increased E2 level (95%
CI: 0.5% – 2.7%), after adjusting for age. Among HRT
users (data not shown), there was significant association
between BMI and FSH (p < 0.01), but not between BMI
and the other hormones analysed (adjusted for age and
estrogen dosage category).
Hormone levels among postmenopausal women not taking 
HRT
There was negative correlation between time since meno-
pause and plasma E2 levels (r = -0.16, p = 0.03) and P4 (r
= -0.29, p < 0.01), and positive correlation between SHBG
levels and time since menopause (r = 0.15 and p = 0.04).
FSH levels were not significantly correlated with time
since menopause.
There was no statistically significant difference in hor-
mone levels between the samples received within 24
hours and those transported over 2, 3 or 4 or more days
among either pre-/perimenopausal or postmenopausal
women (data not shown). Similarly, there was no statisti-
cally significant difference in plasma level between fasting
and non-fasting subjects for any of the hormones meas-
ured, and lipaemia (n = 13) and haemolysis (n = 30),
encountered by visual examination, did not influence the
hormone levels (data not shown).
Premenopausal women
Figure 4 shows plasma levels of E2, P4 and FSH, according
to days since menstruation among premenopausal
women who reported having regular periods and who
filled in the date of the first day of their most recent men-
struation (n = 62). Although there were few women in
each two-day period (n = 1–8), the pattern of hormonal
variation throughout the menstrual cycle was recogniza-
ble both for the gonadal hormones and FSH. Progester-
one levels > 20 nmol/L were only found among women in
their luteal phase (≥15. day). There was no recognizable
cyclic hormone pattern among the 20 perimenopausal
women who had reported their menstruation date. One
woman used an oral contraceptive, a progestagen-only
pill.
Flow chart of menopausal status classification in the study  sample Figure 2
Flow chart of menopausal status classification in the 
study sample. Level c: 16 postmenopausal women not 
using HRT had premenopausal plasma levels of E2 and FSH, 
including 2 of the 9 women reporting irregular menses, while 
14 of the 30 women reporting irregular menses had post-
menopausal plasma levels.
Redistribution
according to plasma
levels of E2 and FSH
Women with irregular
menses distributed
according to age ≥53
Self-reported
menopausal status
2-page questionnaire
331 postmeno. 94 premeno.
317 78
16 14
92 premeno. 333 postmeno.
9≥53 y 30<53 y
324 no menses 62 regular menses 39 irregular m.
425 women
a
c
b
Table 2: Geometric mean plasma levels3 of E2, FSH, P4 and SHBG according to use of HRT among postmenopausal women
E2 dosage category E2
¤ nmol/L FSH¶ IU/L P4 nmol/L SHBG‡ nmol/L
n 95% CI 95% CI 95% CI 95% CI
No HRT 2651 0.07 (0.06–0.07) 69.6 (65.9–73.5) 0,82 (0.76–0.89) 42.4 (40.2–44.8)
HRT
HRT without E2 20 0.07 (0.06–0.08) 53.4 (44.0–64.9) 0,65 (0.49–0.87) 34.9 (28.7–42.4)
Vaginal E2 5 0.07 (0.05–0.10) 70.4 (47.8–104) 0,99 (0.56–1.76) 33.4 (22.6–49.4)
Patches 9 0.15 (0.12–0.19) 36.4 (27.3–48.5) 1,05 (0.68–1.61) 47.0 (35.1–62.8)
Oral 1 mg 232 0.23 (0.20–0.27) 36.9 (30.6–44.6) 0,46 (0.35–0.60) 52.1 (43.4–62.5)
Oral 2 mg 9 0.29 (0.22–0.38) 18.7 (14.1–25.0) 0,79 (0.51–1.21) 62.5 (46.8–83.6)
ANCOVA3 p < 0.01 p < 0.01 p < 0.01 p < 0.01
1FSH: n = 252
2 FSH: n = 21
3 Covariates included in addition to age: ‡ BMI, ¶ BMI and alcohol, ¤ BMI and BMI*age interaction term. Parity did not contribute significantly to the 
model for any of the analyses, and was omitted.BMC Women's Health 2008, 8:1 http://www.biomedcentral.com/1472-6874/8/1
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Validation of self-reported questionnaire information on 
menopausal status and hormone use
Sensitivity and specificity for the variable "menopausal
status" defined by the two questionnaires used is shown
in Table 4. The 66 HRT users were excluded from this anal-
ysis. Sensitivity was higher in the two-page questionnaire
accompanying the blood sample (p < 0.05). The eight-
page questionnaire scored higher on specificity (p < 0.01).
Out of 41 self-reported users of systemically-administered
E2 preparations, 39 women (88%) had E2 levels above the
confidence interval of non-users. Thus, self-reported HRT
use was confirmed by the hormone levels. Among the 265
self-reported non-users, seven women had E2 levels ≥ 0.20
nmol/L. According to the preceding eight-page question-
naire, six out of the seven women reported being pre- or
perimenopausal or uncertain regarding menopausal sta-
tus six months before the blood draw. At the same time,
they also reported being non-users, they did not state their
age at menopause, and all seven were younger than 53
years old. Hence, they were probably perimenopausal at
the time of blood draw, and not misclassified HRT users.
On the basis of this, we conclude that the specificity of the
questionnaire variable "current HRT use" is 100%.
Among 78 women with uncertain menopausal status due
to hysterectomy, use of HRT, etc., who according to the
eight-page questionnaire were defined as postmenopau-
sal, based on age ≥ 53 years, 4 were misclassified accord-
ing to plasma hormone levels.
Discussion
The associations found between current HRT use and
plasma levels of E2  confirm previous reports [10-12].
Transdermal E2 50  μg/day, which is the Defined Daily
Dose (DDD) [22] for E2 patches, should give approxi-
mately the same plasma E2 levels as oral 1 mg E2. We
merged use of patches into one category because there
were only 9 users; 5 did not report the dose and the
remaining 4 used 50 μg/day or less. Assuming that
women in 2005 used the lowest possible dose, it is likely
that the average dose among these women was lower than
50 μg/day, and that the plasma levels of E2 should be
lower for patches than for oral 1 mg E2. Users of HRT for
vaginal application were not expected to differ much from
non-users regarding plasma level of E2. The vaginal tablet
is applied twice a week (maintenance dosage) and reports
from clinical trials show that blood E2  levels remain
within the normal range of postmenopausal women, even
with long-term treatment [23,24]. The confidence inter-
vals of the three systemically-administered HRT groups
Table 3: Geometric mean plasma levels* of E2, FSH, P4 and SHBG according to BMI among postmenopausal women not using HRT
E2 nmol/L FSH IU/L P4 nmol/L SHBG nmol/L
n 95% CI 95% CI 95% CI 95% CI
BMI (kg/m2)
BMI < 25 137 0.07 (0.06–0.07) 76.7 (71.8–81.9) 0.87 (0.78–0.97) 51.8 (48.2–55.7)
25 ≤ BMI < 30 91 0.07 (0.06–0.07) 66.3 (61.2–71.9) 0.78 (0.68–0.89) 35.9 (32.8–39.2)
BMI ≥ 30 37 0.08 (0.07–0.09) 52.0 (45.8–59.1) 0.74 (0.61–0.91) 29.1 (25.3–33.5)
ANCOVA* p = 0.08 p < 0.01 p = 0.25 p < 0.01
* Adjusted for age. The covariates alcohol and parity did not contribute significantly to the model for any of the analyses, and was omitted.
Plasma levels of estradiol and FSH according to estradiol dos- age and rout of administration Figure 3
Plasma levels of estradiol and FSH according to 
estradiol dosage and rout of administration. Geomet-
ric mean ± 95% CI, premenopausal levels are included for 
comparison.
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are partly overlapping, reflecting insufficient power to
conclude that the plasma levels are different.
The increase in FSH levels as a woman approaches meno-
pause is a result of reduced ovarian inhibin synthesis and
increased activin synthesis [25], and it has been assumed
that FSH is not influenced by exogenous estrogen supple-
ments during menopause [26]. Pharmacokinetic studies
of HRT rarely measure FSH levels, nor did NHS [10] in
their population-based study on HRT users. However,
there are some reports which show a decrease in FSH lev-
els during the long-term use of both oral [27,28] and
transdermal E2 [29]. Our results suggest that exogenous E2
has some effect on FSH levels.
It was not expected that P4 levels would be influenced by
HRT use. Although we found differences in P4 levels across
categories of HRT use, there was no association with E2
dosage. For the purpose of validation, it would have been
rational to measure plasma levels of NETA rather than P4
among HRT users, however this was not feasible with our
available methods at the time of analysis.
During daily use of oral HRT, the half life of E2 at a steady
state is 15–25 hours, due to sequestration in adipose tis-
sue and enterohepatic recycling [30]. Several reports also
show that the use of E2 preparations increases the SHBG
plasma concentration, which would increase the blood
depot of E2. However, this applies to the use of CEE to a
greater extent than 17-β-estradiol preparations [31,32]. In
addition, oral rather than topical preparations seem to
increase SHBG levels, due to the liver first pass effect
[11,12,31,32]. This is in accordance with our results,
showing that differences in SHBG levels across HRT cate-
gories are mainly due to significantly increased levels
among the users of oral preparations.
The results on the correlation between time since meno-
pause and levels of E2, FSH and SHBG are in accordance
with previous reports [33,34]. Plasma FSH levels are
already high at menopause, while the E2 levels are still
dropping.
The lack of association between BMI and HRT use sup-
ports conclusions from previous reports [35-37]. The
association found between BMI and hormone levels is
also in accordance with established knowledge. The
absence of a stronger relationship than the one found
between E2 and BMI may be due to the assay used. There
are reports showing that direct immunoassays are ham-
pered by insufficient sensitivity and specificity when
measuring low concentrations of steroids, e.g. E2 among
postmenopausal women [38]. If the E2 levels are artifi-
cially high in the low range, this would weaken the asso-
ciation. It could also be the reason why the ANCOVA did
not show any significant increase across BMI categories, or
alternatively this could be due to lack of power. We may
also suggest a possible effect of BMI in increasing the bio-
availability of estradiol through lower levels of SHBG,
which is in accordance with previous findings [6,13]. We
did not measure estrone (E1), which may be a better
biomarker of estrogen synthesis in adipose tissue among
postmenopausal women, although levels of endogenous
estradiol and estrone are highly correlated [6,39].
Using plasma levels of sex hormones to define a woman
as premenopausal would be difficult, due to the variation
in hormone levels throughout the menstrual cycle. In
addition, the menstrual cycle changes as the woman
approaches menopause [33,34,40]. The follicular phase
shortens; FSH levels begin to increase, and E2 levels subse-
quently decrease. Although we are not trying to validate
the self-reported day of menstrual cycle, the fact that the
Plasma levels of progesterone, estradiol and FSH according  to days since most recent menstruation among 62 premeno- pausal women Figure 4
Plasma levels of progesterone, estradiol and FSH 
according to days since most recent menstruation 
among 62 premenopausal women. Geometric mean ± 
1SE, 2 period moving average.
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cyclic pattern of plasma sex hormones is visible at all in
this rather small group of older premenopausal women
provides some assurance in this matter.
We have used plasma levels of E2 and FSH as the gold
standard in our validation of self-reported questionnaire
information on HRT use and menopausal status. Whether
the gold standard chosen is a proper gold standard is
always debatable. However, hormone levels were consid-
ered to be the best available instrument. To draw the line
between pre- and postmenopause, we have used plasma
levels of FSH > 26 IU/L and E2 < 0.20 nmol/L as the cut-
off point. Several clinical trials conducted among post-
menopausal subjects use FSH levels > 30–50 IU/L and/or
E2  levels < 0.07–0.15 nmol/L as inclusion criteria
[11,12,30]. These rather strict criteria are imperative in
clinical trials, to ensure that all the participants are post-
menopausal. However, this generates a rather large group
of false negatives, which is inappropriate to a validation.
Furthermore, since the premenopausal E2 and FSH plasma
levels for 14 out of the 16 women reclassified as premen-
opausal may be explained from information from the
eight-page questionnaire (hysterectomy, use of hormone
containing intrauterine device, etc.), our cut-off point
seems to be well-chosen.
Since the plasma E2 levels among women using vaginal
E2-preparations were no different from those of non-
users, our validation of the variable "current HRT use" had
to be based on the women using systemically-adminis-
tered E2-containing preparations. However, we see no rea-
son why the route of administration should influence the
women's ability to answer the question, and have
extended the result to include all HRT use. The agreement
found between self-reported HRT use and plasma E2 levels
supports previous findings from validation studies com-
paring self-reported HRT use with prescription data
[41,42].
It makes sense to find a lower sensitivity for the eight-page
questionnaire, because some women could have become
postmenopausal during the six-month lapse until the
blood draw. On the other hand, the specificity for the
eight-page questionnaire may be artificially high, since
some of the premenopausal women will be reported as
postmenopausal on the two-page questionnaire six
months later, although they are probably in a perimeno-
pausal state. Due to the low misclassification rate, it seems
reasonable to continue using age ≥53 as the cut-off point
when defining menopausal status in cases of uncertainty.
Strengths and limitations
The NOWAC study has the advantage of being popula-
tion-based and prospective. The opportunity of random
sampling from the complete Central Population Register,
together with high response rates, provides a representa-
tive sample of the Norwegian female population aged
48–62 years [43]. The two-page questionnaire accompa-
nying the blood sample provides detailed and updated
information on central variables such as menstruation sta-
tus, weight and HRT use, which are complementary to the
preceding eight-page questionnaire. Results show that it is
especially valuable to be able to differentiate between dif-
ferent types of HRT. The effect of HRT exposure will vary
between populations using different HRT regimens, par-
ticularly with respect to estrogenic carcinogenicity.
Compliance with HRT is an important determinant for
the accurate measurement of HRT use. With 86–95% of
the women showing compliance with HRT use, we do not
Table 4: Validation of the menstrual status definition according to questionnaire information
Classification according to plasma E2 and FSH levels
P o s t -P r e -T o t a l
Classification according to two-page questionnaire
Post- 240 27 267
Pre- 20 72 92
Total 260 99 359
Sensitivity: 240/260 = 92% (95% CI 89–96%)
Specificity: 72/99 = 73% (95% CI 64–82%)
Classification according to eight-page questionnaire
Post- 229 11 240
Pre- 29 86 115
Unknown 2 2 4
Total 260 99 359
Sensitivity: 229/260 = 88% (95% CI 84–92%)
Specificity: 86/99 = 87% (95% CI 80–94%)BMC Women's Health 2008, 8:1 http://www.biomedcentral.com/1472-6874/8/1
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consider lack of compliance to be a significant source of
bias in our study.
Probably due to small sample sizes, the assumption of
equal variances was violated in the ANCOVA analysis of
differences between HRT categories. This causes some
concern and the results must be interpreted accordingly.
Even so, the very low p-values suggest that the results for
E2 and FSH are valid.
Reports on the validity of self-reported body-size gener-
ally show that particularly obese people tend to underes-
timate their weight/waist circumference [44,45]. In the
present study, there is an increase in weight (mean: +0.6
kg) between the eight-page questionnaire and the two-
page questionnaire six months later and the increase is
higher among the women who had their weight measured
at their general physician's office (n = 49). This should not
influence our analyses to the degree that the associations
found are artefacts. However, if the BMI is under-esti-
mated, the change in hormone levels per increased unit of
BMI could be over-estimated.
Choosing plasma or serum is a trade-off between rational
collection logistics and the broadest assortment of feasible
analyses. Not all general physicians' offices have equip-
ment for blood centrifugation, and at the beginning of the
NOWAC blood specimen collection in 2002 the range of
future analyses had not yet been determined. With the
aim of collecting blood from as many participants as pos-
sible, it was decided to build a plasma biobank. Citrate
was chosen as the anticoagulant, due to the collaboration
of NOWAC with EPIC and their collection of citrate
plasma. Citrate plasma is not the optimum matrix for
immunometry analyses. Although the verification analy-
sis performed by the laboratory did not show alarming
inconsistencies, the results must be interpreted accord-
ingly, especially in view of the general limitations of direct
immunoassays mentioned above.
A transport delay of over two days could potentially inter-
fere with our measurements. Several studies have con-
cluded that sex hormones FSH and SHBG are fairly stable
with regard to transport conditions, temperature varia-
tions and delayed processing [46-50]. These reports are
not based on an analysis of citrate plasma. However, in
our sample there were no statistically significant differ-
ences due to transport delay, and we did not exclude any
blood samples on these grounds. The analytical methods
used are fairly robust with regard to interference by hae-
moglobin and triglycerides, and since we found no differ-
ences due to lipaemia or haemolysis these samples were
not excluded from the analysis. Due to the study design,
blood samples were not drawn at the same time of day,
nor were the women requested to be fasting. However, we
found no differences in hormone levels due to fasting and
have not adjusted our results according to time since last
meal.
Because of the cross-sectional nature of this study, we can-
not draw any conclusions regarding causal association
based on our results. However, imminent gene-expression
analyses and future follow-up of the women in our popu-
lation sample will contribute to our knowledge on causal
relationships.
Conclusion
Users of systemically-administered E2-containing HRT
preparations have plasma E2 and FSH levels comparable
to those of premenopausal women, while users of vaginal
E2  preparations remain within postmenopausal levels.
There is no difference in BMI between HRT users and non-
users, but increased BMI is associated with increased E2
and decreased FSH and SHBG levels among non-users.
The NOWAC questionnaires provide valid information
on current hormone use and menopausal status among
Norwegian women who are 48–62 years old.
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